<DOC>
	<DOCNO>NCT02679261</DOCNO>
	<brief_summary>Bicuspid Aortic Valve ( BAV ) common congenital heart disease affect 1-2 % population . The aortic dilation aortic valve degeneration common complication patient BAV . Statins show reduction expression metalloproteinases extracellular matrix observe aortic aneurism . Several retrospective study suggest benefit statin reduce aortic dilation patient BAV . Moreover , although statin show useful progression aortic stenosis , different study suggest high profit valve affection severe . The objective study determine whether atorvastatin effective reduce progression aortic dilation patient BAV .</brief_summary>
	<brief_title>Evaluating Effectiveness Atorvastatin Progression Aortic Dilatation Valvular Degeneration Patients With Bicuspid Aortic Valve</brief_title>
	<detailed_description>BICATOR multicentre ( 8 centre ) , randomise , double-blind placebo-controlled clinical trial aim evaluate effect atorvastatin reduce progression aortic dilation patient BAV . The primary outcome determine whether atorvastatin effective reduce aortic dilation BAV secondary outcome define atorvastatin treatment slow progression aortic valve degeneration ( valve calcification ) 3 year follow-up period . 220 patient include ( 110 atorvastatin - 110 placebo ) .</detailed_description>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Patients ≥ 18 year old BAV confirm transthoracic echocardiography ( case doubt technique require : transesophageal echocardiography CT confirm diagnosis ) . Valve dysfunction moderate : case aortic stenosis average gradient &lt; 30 mmHg case aortic regurgitation vena contracta &lt; 7 mm jet &lt; 10 mm . Aortic valve show severe calcification transthoracic echocardiography . Ascending aortic diameter ( Valsalva sinus tubular ascend aorta ) ≤ 50 mm . The patient must give consent form sign . Patients young 18 . Patients uncontrolled hypertension history risk diabetes mellitus . Patients receive statin treatment lipid lower drug indication treat accord current clinical practice guideline . Previous cardiac surgery surgery segment aorta . Previous aortic dissection and/or aortic coarctation . NYHA functional class III IV . Presence antecedent liver failure ( transaminase &gt; 2 fold superior limit normal level accord local laboratory ) , renal failure ( creatinine clearance &lt; 30ml/min creatinine &gt; 2.5mg/dl ) , myopathy creatine kinase level &gt; 5 fold superior limit normality , gastrointestinal , hematologic endocrine disease situation accord investigator criterion could affect study treatment evaluation . Hypersensitivity , intolerance contraindication component study drug contrast use CT. Pregnancy , breastfeed desire pregnancy study period . A negative pregnancy test ( negative gonadotropin ) require fertile woman participate study . Participation another drug study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Aortic dilation</keyword>
	<keyword>Statins</keyword>
	<keyword>Aortic degeneration</keyword>
</DOC>